Impact of highly active antiretroviral therapy on the prevalence of oral lesions in HIV-positive patients: a systematic review and meta-analysis

Mittler, 1996, T-cell homeostasis, competition, and drift: AIDS as HIV-accelerated senescence of the immune repertoire, J Acquir Immune Defic Syndr Hum Retrovirol, 12, 233, 10.1097/00042560-199607000-00003 Lawn, 2006, Immune reconstitution disease associated with parasitic infections following antiretroviral treatment, Parasite Immunol, 28, 625 Li, 1998, Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease, Lancet, 351, 1682, 10.1016/S0140-6736(97)10291-4 Hammer, 2008, Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society USA panel, JAMA, 300, 555, 10.1001/jama.300.5.555 Ho, 1995, Time to hit HIV, early and hard, N Engl J Med, 333, 450, 10.1056/NEJM199508173330710 Murdoch, 2007, Immune reconstitution inflammatory syndrome (IRIS): a review of common infectious manifestations and treatment options, AIDS Res Ther, 4, 9, 10.1186/1742-6405-4-9 Schimidt-Westhausen, 2000, Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy, J Oral Pathol Med, 29, 336, 10.1034/j.1600-0714.2000.290708.x Tappuni, 2001, The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients: a UK study, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 92, 623, 10.1067/moe.2001.118902 Peppes, 2013, Oral lesions frequency in HIV-positive patients at a tertiary hospital, Southern Brazil, Braz J Oral Sci, 12, 216, 10.1590/S1677-32252013000300012 Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, PLoS Med, 6, e1000100, 10.1371/journal.pmed.1000100 EC-Clearinghouse on Oral Problems Related to HIV Infection and WHO Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus, 1993, Classification and diagnostic criteria for oral lesions in HIV infection, J Oral Pathol Med, 22, 289 Shiboski, 2009, The Oral HIV/AIDS Research Alliance: updated case definitions of oral disease endpoints, J Oral Pathol Med, 38, 481, 10.1111/j.1600-0714.2009.00749.x Joanna Briggs Institute, 2014 Hamza, 2006, Oral manifestations of HIV infections in children and adults receiving highly active anti-retroviral therapy [HAART] in Dar es Salaam, Tanzania, BCM Oral Health, 6, 12, 10.1186/1472-6831-6-12 Lourenço, 2008, Oral lesions in HIV infected individuals from Ribeirão Preto, Brazil, Med Oral Patol Oral Cir Bucal, 13, E281 Nittayananta, 2010, Effects of long-term use of HAART on oral health status of HIV-infected subjects, J Oral Pathol Med, 39, 397, 10.1111/j.1600-0714.2009.00826.x Mthethwa, 2013, The prevalence of HIV associated oral lesions among adults in the era of HAART, SADJ, 68, 364 Naidu, 2013, Oral lesions and immune status of HIV infected adults from eastern Nepal, J Clin Exp Dent, 5, e1, 10.4317/jced.50888 Patil, 2015, The effect of highly active antiretroviral therapy on the prevalence of oral manifestation in human immunodeficiency virus-infected patients in Karnataka, India, Eur J Dent, 9, 47, 10.4103/1305-7456.149640 Phillips, 2006, The CD4 lymphocyte count and risk of clinical progression, Curr Opin HIV AIDS, 1, 43, 10.1097/01.COH.0000194106.12816.b1 Onakewhor, 2006, Determination of maternal immune status of HIV positive women using CD4 count level: implications for the Nigeria PMTCT program, Sahel Med J, 9, 117 Patton, 2002, Prevalence and classification of HIV-associated oral lesions, Oral Dis, 8, 98, 10.1034/j.1601-0825.2002.00020.x Coogan, 2005, Oral lesions in infection with human immunodeficiency virus, Bull World Health Organ, 83, 700 Palmer, 1996, Aetiological factors for oral manifestations of HIV, Oral Dis, 2, 193, 10.1111/j.1601-0825.1996.tb00223.x Perera, 2012, Prevalence of oral mucosal lesions in adults undergoing highly active antiretroviral therapy in Hong Kong, J Investig Clin Dent, 3, 208, 10.1111/j.2041-1626.2012.00124.x Ramirez-Amador, 2003, The changing clinical spectrum of human immunodeficiency virus (HIV)-related oral lesions in 1,000 consecutive patients: a 12 year study in a referral center in Mexico, Medicine (Baltimore), 82, 39, 10.1097/00005792-200301000-00004 Rubinstein, 2014, Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges, AIDS, 28, 453, 10.1097/QAD.0000000000000071 Maskew, 2013, Treatment response and mortality among patients starting antiretroviral therapy with and without Kaposi sarcoma: a cohort study, PLoS One, 8, e64392, 10.1371/journal.pone.0064392 Rohner, 2014, HHV-8 seroprevalence: a global view, Syst Rev, 3, 11, 10.1186/2046-4053-3-11 Balaji, 2016, Recapitulation of acquired immuno deficiency syndrome associated Kaposi’s sarcoma, Indian J Sex Transm Dis, 37, 115, 10.4103/0253-7184.192120 Lupia R, Wabuyia PB, Otiato P, Fang CT, Tsai FJ. Risk factors for Kaposi’s sarcoma in human immunodeficiency virus patients after initiation of antiretroviral therapy: a nested case control study in Kenya. J Microbiol Immunol Infect 2015 Dec 2. pii: S1684-1182(15)00906-8. Eyeson, 2002, Oral manifestations of an HIV positive cohort in the era of highly active anti-retroviral therapy (HAART) in South London, J Oral Pathol Med, 31, 169, 10.1034/j.1600-0714.2002.310308.x Navazesh, 2002, Saliva: a fountain of opportunity, J Calif Dent Assoc, 30, 783, 10.1080/19424396.2002.12223320